Regulators view of HVD drugs [Regulatives / Guidelines]

posted by DavidManteigas – Portugal, 2017-05-16 14:41 (2833 d 02:56 ago) – Posting: # 17357
Views: 22,991

Hi Helmut,

For the sake of curiosity, in your opinion should a regulator approve a generic submited as "highly variable" although all the previous trials reported low CV's? Technically, the criteria are well defined and no objection should be raised in principle. However, should a study that reports an high variation, when all the previous information reports otherwise, be considered scientifically sound for the demonstration of bioequivalence? Ideally, regulators would publish in their product-specific guidelines which compounds could be considered "highly variable"...

Regards,
David

Complete thread:

UA Flag
Activity
 Admin contact
23,381 posts in 4,914 threads, 1,663 registered users;
42 visitors (0 registered, 42 guests [including 9 identified bots]).
Forum time: 16:38 CET (Europe/Vienna)

Science is built up with facts, as a house is with stones.
But a collection of facts is no more a science
than a heap of stones is a house.    Henri Poincaré

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5